secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVADEL PHARMACEUTICALS PLC (—)
CIK:        0001012477
Form:       8-K
Filed at:   2024-05-21T23:59:59+00:00
Accession:  0001104659-24-063653
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avadel Pharmaceuticals appoints Naseem Amin, M.D. to Board of Directors
-----------------------------------------------------------------------

- Naseem Amin appointed effective May 17, 2024, as independent director.
- Granted option to purchase 49,500 shares at $15.94, vesting over three years.
- Amin is CEO of Orphalan SA with 30 years experience in biopharma and venture capital.
- Board cites Amin's expertise to support commercial launch of LUMRYZ for narcolepsy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1012477/000110465924063653/0001104659-24-063653-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1012477/000110465924063653/tm2414924d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-063653

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer